Foxx Development Holdings Inc. (NASDAQ:FOXX) Short Interest Update

Foxx Development Holdings Inc. (NASDAQ:FOXX) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 19,770 shares, a decline of 41.2% from the July 15th total of 33,622 shares. Based on an average daily trading volume, of 8,351 shares, the short-interest ratio is currently 2.4 days. Currently, 0.4% of the company’s shares are sold short.

Foxx Development Trading Up 1.2%

Shares of FOXX stock traded up $0.03 during trading hours on Wednesday, hitting $2.58. 895 shares of the company were exchanged, compared to its average volume of 654,526. Foxx Development has a 52 week low of $1.71 and a 52 week high of $7.90. The business has a 50 day moving average of $2.92 and a two-hundred day moving average of $4.04. The company has a market capitalization of $18.16 million, a PE ratio of -0.37 and a beta of -0.35.

Foxx Development (NASDAQ:FOXX) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($5.19) EPS for the quarter. The company had revenue of $8.67 million for the quarter.

Institutional Trading of Foxx Development

An institutional investor recently raised its stake in Foxx Development stock. JPMorgan Chase & Co. lifted its position in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX) by 170.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,947 shares of the company’s stock after buying an additional 3,121 shares during the period. JPMorgan Chase & Co. owned about 0.07% of Foxx Development worth $27,000 at the end of the most recent quarter. 60.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Foxx Development Company Profile

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.